Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Drug Manufacturing Technology Could Improve Personalized Medicine

XTALKS VITALS NEWS

3-D Printing

According to the researchers, this new tablet fabrication method will allow drugmakers to combine multiple different pharmaceuticals – with different rates if release – into a single pill.

Share this!

May 27, 2016 | by Sarah Massey, M.Sc.

Engineers from the National University of Singapore (NUS), have developed a new way to manufacture personalized medicine that is less expensive and more convenient than currently-available methods. According to the researchers, this new tablet fabrication method will allow drugmakers to combine multiple different pharmaceuticals – with different rates if release – into a single pill Tweet: Combine multiple different pharmaceuticals – with different rates if release – into a single pill. http://ctt.ec/68NbM+.

In order to get the optimal therapeutic effect from a given medication, the drugs must be released at a set rate to be absorbed by the body. This means that patients taking multiple medications must take them on a complicated schedule, making sure to take some drugs together and avoid combining others.

Current tablet manufacturing methods – including 3-D printing – do provide some level of design flexibility, however these methods have many limitations. Most existing drug production methods can only produce low-dose pills that are released following a non-continuous profile. Assistant Professor Soh Siowling and PhD student Ms. Sun Yajuan from the Department of Chemical and Biomolecular Engineering at the NUS Faculty of Engineering, say their system will solve many of these problems.

“For a long time, personalized tablet has been a mere concept as it was far too complex or expensive to be realized,” said Siowling. “This new tablet fabrication method is a game changer – it is technically simple, relatively inexpensive and versatile. It can be applied at individualized settings where physicians could produce customized pills on the spot for patients, or in mass production settings by pharmaceutical companies.”



In contrast to other 3-D printing methods which build the tablet one layer at a time, the tableting process designed by Siowling and his colleagues is composed of three different components. One of these components – a specialized polymer – contains the drug, which can be manufactured in a specific shape to ensure optimal release of the payload.

According to the researchers, physicians may be able to use this method to print personalized treatments for patients at the point-of-care. The system would only require the doctor to input the drugs’ desired release profile into a computer software program, and use a standard 3-D printer to fabricate the tablets.

As it’s often necessary for patients to take multiple drugs at once, the researchers say this method could be used to manufacture pills containing multiple active pharmaceutical ingredients. By adjusting the shape of each polymer-associated drug, a single pill with multiple drug release profiles can be made.


Keywords: Personalized Medicine, Drug Manufacturing, 3-D Printing


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.